Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance. Issue 1 (29th February 2020)

• Record Type: Journal Article
• Authors: Song, Jinming; Hussaini, Mohammad; Qin, Dahui; Zhang, Xiaohui; Shao, Haipeng; Zhang, Ling; Gajzer, David; Basra, Pukhraz; Moscinski, Lynn; Zhang, Hailing
• Is Part Of: American journal of clinical pathology. Volume 154:Issue 1(2020)
• Page Start: 48
• Page End: 56
• Publication Date: 2020-02-29
• Subjects: DNMT3A -- SF3B1 -- Mutation -- MDS -- CCUS -- SF3B1/DNMT3A; Diagnosis, Laboratory -- Periodicals; Pathology -- Periodicals; 616.07
• DOI: 10.1093/ajcp/aqaa016
• Languages: English
• ISSNs: 0002-9173

Abstract

Abstract: Objectives: To compare the clinical significance of SF3B1 / DNMT3A Comutations with SF3B1 or DNMT3A mutation alone in myelodysplastic syndrome (MDS) and clonal cytopenia of undetermined significance (CCUS). Methods: We identified and compared 31 patients with only DNMT3A mutation, 48 patients with only SF3B1 mutation, and 16 patients with only SF3B1 / DNMT3A comutations. Results: SF3B1 / DNMT3A comutations were found to be more common in MDS, whereas DNMT3A mutation alone was more common in CCUS. The patients with SF3B1 / DNMT3A comutations were less likely to have poor cytogenetics than patients with DNMT3A mutation alone. Patients with SF3B1 / DNMT3A comutations showed significantly longer median survival time and better overall survival than patients with DNMT3A mutation alone. Conclusions: Patients with SF3B1 / DNMT3A comutations appear to have better clinical outcomes than patients with isolated DNMT3A mutation. These findings suggest that the favorable prognosis of SF3B1 mutation in is not abrogated by the concurrent presence of a DNMT3A mutation.